Bli medlem
Bli medlem

Du är här


Enzymatica AB: Enzymatica moves forward its year-end report for 2015

Enzymatica will move forward the announcement of its year-end report 2015 from
February 16 to February 15, 2016. The reason is that the company prefers to
announce the year-end report the same day as the Extraordinary General
Meeting takes place, that is February 15, on account of Enzymatica's bid on
the Icelandic R&D company Zymetech.

For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB

Tel: +46 708-86 53 70 |

About Enzymatica AB

Enzymatica is a life science company whose business concept is to offer
effective help against some of our most common diseases where viruses or
bacteria play a decisive role. Over a short period the company has developed
a unique oral spray for colds, ColdZyme®, and launched it on six markets. The
product has become one of the leading articles for colds in Swedish
pharmacies. Development includes medical devices in upper respiratory
infections and oral health, and veterinary products. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North. For more
information, please

Enzymatica's certified adviser is Erik Penser Bankaktiebolag.

Press Release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.